| Autor: |
Diogo Ramalho, André Araújo, Gustavo Rocha, Filipa Duarte-Ribeiro |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
European Journal of Case Reports in Internal Medicine (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2284-2594 |
| DOI: |
10.12890/2021_003099 |
| Popis: |
Pituitary adenomas are the most common cause of hypopituitarism associated with pituitary enlargement, but other aetiologies have been emerging, namely immune checkpoint inhibitor-induced hypophysitis (ipilimumab, nivolumab and pembrolizumab). Secukinumab is a recently approved human monoclonal antibody used for the treatment of psoriasis, with no know reported cases of hypophysitis. We describe a challenging case of panhypopituitarism in a patient with a pituitary incidentaloma and a temporal relationship between secukinumab initiation and the manifestation of clinical features suggestive of hypopituitarism. In such intricate work-up, the differential diagnoses should be carefully considered, taking into account the therapeutic and prognostic implications. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
